There’s a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on Coffee Holding Co (JVA) and Chromadex Corp (CDXC) with bullish sentiments.
Coffee Holding Co (JVA)
Maxim Group analyst Stephen Anderson maintained a Buy rating on Coffee Holding Co today and set a price target of $11. The company’s shares closed yesterday at $6.55.
Anderson observed:
“We maintain our Buy rating on Coffee Holding Company (JVA) and raise our price target to $11, from $9, following our meeting with CEO Andy Gordon last week. We expect management to release F1Q19 (January) results next week and model quarterly EPS of $0.12, which is unchanged from our prior estimate. We raise our FY19 EPS estimate to $0.35, from $0.32 and our FY20 EPS estimate to $0.58, from $0.56, as we model potential upside from new private- label business. We also introduce our FY21 EPS estimate of $0.74. Our EPS estimates do not assume a potential launch of a CBD (cannabidiol)- infused coffee product.”
According to TipRanks.com, Anderson is a 5-star analyst with an average return of 10.4% and a 65.3% success rate. Anderson covers the Services sector, focusing on stocks such as Dave & Busters Entertainment, Good Times Restaurants Inc, and Dine Brands Global Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Coffee Holding Co with a $11 average price target.
See today’s analyst top recommended stocks >>
Chromadex Corp (CDXC)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Chromadex Corp, with a price target of $7. The company’s shares closed yesterday at $3.43.
Selvaraju wrote:
“Valuation methodology, risks and uncertainties. We apply a 26.6x EV-to-EBITDA multiple applied to our 2020 EBITDA per share estimate of $0.38, discounted back at a 12% rate, which yields a price objective of approximately $7.00 per share.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -9.6% and a 32.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chromadex Corp with a $7 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
